{
    "clinical_study": {
        "@rank": "51806", 
        "arm_group": [
            {
                "arm_group_label": "Neonatal", 
                "description": "Neonates born to pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection."
            }, 
            {
                "arm_group_label": "Maternal", 
                "description": "Pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection"
            }
        ], 
        "biospec_descr": {
            "textblock": "Blood specimens will be obtained to test magnesium levels in the mother and neonate."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Determine significant correlations between maternal serum magnesium levels, and maternal and\n      neonatal outcomes."
        }, 
        "brief_title": "PK/PD Modeling of Magnesium in the Mother and Neonate", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Magnesium Sulfate Pharmacokinetics and Pharmacodynamics", 
        "detailed_description": {
            "textblock": "We will construct a pharmacokinetic and pharmacodynamic model of intravenous magnesium\n      sulfate administered antenatally to expectant mothers and exposed fetuses with the aim of\n      optimizing maternal and fetal outcomes while preventing maternal and neonatal overdosing and\n      morbidity associated with current magnesium treatment protocols.  Once we have developed a\n      PK/PD model in our own hospital cohort, we will apply this model to a large existing NICHD\n      database to mathematically calculate optimal dosing protocols."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pregnant women ages 18-45 years\n\n          -  Magnesium sulfate exposure for preeclampsia, tocolysis, or neuroprotection\n\n          -  Neonates (male or female) born at 24-42 weeks gestation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Pregnant women and neonates exposed to magnesium sulfate infusion around the time of\n        delivery for one of three reasons: 1.) preeclampsia 2.) tocolysis 3.) neuroprotection."
            }
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709630", 
            "org_study_id": "ID-2803"
        }, 
        "intervention": {
            "arm_group_label": [
                "Neonatal", 
                "Maternal"
            ], 
            "description": "Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.", 
            "intervention_name": "Magnesium sulfate infusion", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Magnesium Sulfate"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 16, 2012", 
        "location": {
            "contact": {
                "email": "bcarvalho@stanford.edu", 
                "last_name": "Brendan Carvalho, M.D.", 
                "phone": "650-861-8607"
            }, 
            "contact_backup": {
                "email": "kbrook@stanford.edu", 
                "last_name": "Kathleen Brookfield, M.D.", 
                "phone": "305.785.1386"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Lucille Packard Children's Hospital at Stanford University Medical Center"
            }, 
            "investigator": {
                "last_name": "Brendan Carvalho, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Pharmacokinetics (PK)/Pharmacodynamics (PD) Modeling of Magnesium Sulfate In the Mother and Exposed Neonate", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pregnant women and neonates exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection will have blood samples drawn at set time points around the time of delivery.", 
            "measure": "Maternal and neonatal blood magnesium levels", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "reference": [
            {
                "PMID": "18753646", 
                "citation": "Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, Iams JD, Wapner RJ, Sorokin Y, Alexander JM, Harper M, Thorp JM Jr, Ramin SM, Malone FD, Carpenter M, Miodovnik M, Moawad A, O'Sullivan MJ, Peaceman AM, Hankins GD, Langer O, Caritis SN, Roberts JM; Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008 Aug 28;359(9):895-905."
            }, 
            {
                "PMID": "19701048", 
                "citation": "Pryde PG, Mittendorf R. Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose. Obstet Gynecol. 2009 Sep;114(3):669-73. Review."
            }, 
            {
                "PMID": "22836873", 
                "citation": "Greenberg MB, Penn AA, Whitaker KR, Kogut EA, El-Sayed YY, Caughey AB, Lyell DJ. Effect of magnesium sulfate exposure on term neonates. J Perinatol. 2013 Mar;33(3):188-93. doi: 10.1038/jp.2012.95. Epub 2012 Jul 26."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709630"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Stanford University", 
            "investigator_full_name": "Brendan Carvalho", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Maternal drug side effects (flushing, sedation, nausea, vomiting, respiratory rate, oxygen saturations, blood pressure, heart rate, and patella tendon reflex depression) will be assessed prospectively.\nNeonatal drug effects: Incidence of cerebral palsy, neonatal mortality, NICU and special care admissions, respiratory distress, intraventricular hemorrhage, necrotizing enterocolitis, hypotonia, feeding difficulties, and diagnosis of hypermagnesemia will be recorded, We will use validated and standardized definitions for diagnoses and all clinical outcome measurements.", 
            "measure": "Maternal and neonatal side effects", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}